Woman with Alzheimer’s hadn’t spoken in 5 years. Then she took a dose of psilocybin and everything changed
A new case report is drawing attention across the psychedelic medicine world after an 80 year old woman with advanced Alzheimer’s disease appeared to regain speech, mobility, continence, and emotional engagement after receiving a high dose of psilocybin containing mushrooms. The report does not show that psilocybin reverses Alzheimer’s. It does, however, suggest something researchers have long wanted to understand: whether some abilities lost in severe dementia may remain hidden rather than fully erased.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and ketamine clinics closest to you as well as other psychedelic therapies in your area.
| Key takeaway | What it means |
|---|---|
| One patient showed striking changes | The case involved a single woman with advanced Alzheimer’s disease. |
| Speech returned temporarily | She began autobiographical conversation about 19 hours after treatment. |
| Other functions improved | Reports included better walking, continence, alertness, and social engagement. |
| This was not a clinical trial | The case was observational and cannot prove cause and effect. |
| More research is needed | The findings should guide controlled studies, not at home use. |
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
What Happened In The Case
According to the case report, the woman had lived with Alzheimer’s symptoms for about 10 years. During the previous five years, she had become largely nonverbal. She also needed help with mobility, dressing, swallowing, toileting, and daily care.
She received 5 grams of Enigma mushrooms, a strain known for high potency. Afterward, she entered a prolonged sleep like state. Her caregivers also observed sweating and suspected fever.
About 19 hours later, she woke and began speaking. The report describes several hours of autobiographical conversation. In the days that followed, she showed more eye contact, better emotional expression, improved walking, and restored urinary continence.
One month later, she received a second supervised session with a smaller dose. The report again noted greater verbal expression, spontaneous humor, emotional imagery, and improved agility.
Why This Matters
Advanced Alzheimer’s is usually treated as a stage of irreversible decline. Care often focuses on comfort, safety, and preserving remaining function.
This case does not overturn that reality. It does suggest that some neural circuits may remain partly accessible, even late in the disease process. Psilocybin may have temporarily changed brain network activity in a way that allowed those capacities to surface.
That idea matters. It shifts the question from “Can Alzheimer’s be cured?” to a more precise research question: Can certain interventions briefly restore access to remaining brain function?
The Necessary Caution
The limits here are significant. This was one patient. There was no placebo group. There were no standardized cognitive tests, brain scans, or biomarker confirmation.
The dose was also high, and the acute effects were physically intense. Psilocybin can carry serious risks, especially for medically fragile patients.
Still, the case gives researchers a reason to look closer. If future studies can test this safely, psilocybin may become part of a larger investigation into neuroplasticity, consciousness, and late stage dementia care. For now, it is not a treatment recommendation. It is a signal worth studying.
